Literature DB >> 21431291

Successful treatment with anti-tumor necrosis factor (anti-TNF)-alpha of proteinuria in a patient with familial mediterranean fever (FMF) resistant to colchicine: anti-TNF drugs and FMF.

S Erten, S F Erten, A Altunoglu.   

Abstract

Familial mediterranean fever (FMF) is an autoinflammatory disease characterized by recurrent attacks of fever, peritonitis, pleuritis, and genetically by autosomal recessive inheritance. The major renal involvement in FMF is the occurrence of amyloidosis that can be prevented by a daily regimen of colchicine. About 5-10% of cases with familial mediterranean fever may be resistant to colchicine. In literature, there is a controversy about the treatment of FMF patients resistant to colchicine. We describe a case with FMF, proteinuria, and bilateral sacroiliitis, which responded to anti-TNF (tumor necrosis factor)-alpha therapy with infliximab and etanercept.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21431291     DOI: 10.1007/s00296-011-1855-5

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN: 0172-8172            Impact factor:   2.631


  10 in total

1.  Successful treatment with infliximab and low-dose methotrexate in a Japanese patient with familial Mediterranean fever.

Authors:  Akinori Nakamura; Masayuki Matsuda; Ko-Ichi Tazawa; Yasuhiro Shimojima; Shu-Ichi Ikeda
Journal:  Intern Med       Date:  2007-08-02       Impact factor: 1.271

Review 2.  Familial Mediterranean fever.

Authors:  E Ben-Chetrit; M Levy
Journal:  Lancet       Date:  1998-02-28       Impact factor: 79.321

3.  Infliximab treatment of Familial Mediterranean fever and its effect on secondary AA amyloidosis.

Authors:  Samy Metyas; Daniel G Arkfeld; Deborah M Forrester; Glenn R Ehresmann
Journal:  J Clin Rheumatol       Date:  2004-06       Impact factor: 3.517

4.  The musculoskeletal manifestations of familial Mediterranean fever in children genetically diagnosed with the disease.

Authors:  R Brik; M Shinawi; L Kasinetz; R Gershoni-Baruch
Journal:  Arthritis Rheum       Date:  2001-06

5.  Familial Mediterranean fever responds well to infliximab: single case experience.

Authors:  Salih Ozgocmen; Levent Ozçakar; Ozge Ardicoglu; Ercan Kocakoc; Arzu Kaya; Adem Kiris
Journal:  Clin Rheumatol       Date:  2005-09-20       Impact factor: 2.980

6.  Etanercept in the treatment of arthritis in a patient with familial Mediterranean fever.

Authors:  O Sakallioglu; A Duzova; S Ozen
Journal:  Clin Exp Rheumatol       Date:  2006 Jul-Aug       Impact factor: 4.473

7.  Seronegative spondyloarthropathy of familial Mediterranean fever.

Authors:  Nurgül Arinci Incel; Meryem Saraçoğlu; H Rana Erdem
Journal:  Rheumatol Int       Date:  2003-01       Impact factor: 2.631

8.  Colchicine nonresponsiveness in familial Mediterranean fever: clinical, genetic, pharmacokinetic, and socioeconomic characterization.

Authors:  Merav Lidar; Jean-Michel Scherrmann; Yael Shinar; Angela Chetrit; Elisabeth Niel; Ruth Gershoni-Baruch; Pnina Langevitz; Avi Livneh
Journal:  Semin Arthritis Rheum       Date:  2004-02       Impact factor: 5.532

9.  Mutations in the gene for familial Mediterranean fever: do they predispose to inflammation?

Authors:  Seza Ozen; Aysin Bakkaloglu; Engin Yilmaz; Ali Duzova; Banu Balci; Rezan Topaloglu; Nesrin Besbas
Journal:  J Rheumatol       Date:  2003-09       Impact factor: 4.666

10.  Familial mediterranean Fever and renal disease.

Authors:  Hatem I El-Shanti
Journal:  Saudi J Kidney Dis Transpl       Date:  2003 Jul-Sep
  10 in total
  5 in total

Review 1.  Infliximab therapy for familial Mediterranean fever-related amyloidosis: case series with long term follow-up.

Authors:  Z Birsin Özçakar; Selçuk Yüksel; Mesiha Ekim; Fatoş Yalçınkaya
Journal:  Clin Rheumatol       Date:  2012-06-07       Impact factor: 2.980

2.  TNF/TNFR axis promotes pyrin inflammasome activation and distinctly modulates pyrin inflammasomopathy.

Authors:  Deepika Sharma; Ankit Malik; Clifford Guy; Peter Vogel; Thirumala-Devi Kanneganti
Journal:  J Clin Invest       Date:  2018-11-19       Impact factor: 14.808

3.  Biotechnological Agents for Patients With Tumor Necrosis Factor Receptor Associated Periodic Syndrome-Therapeutic Outcome and Predictors of Response: Real-Life Data From the AIDA Network.

Authors:  Antonio Vitale; Laura Obici; Marco Cattalini; Giuseppe Lopalco; Giampaolo Merlini; Nicola Ricco; Alessandra Soriano; Francesco La Torre; Elena Verrecchia; Antonella Insalaco; Lorenzo Dagna; Masen Abdel Jaber; Davide Montin; Giacomo Emmi; Luisa Ciarcia; Sara Barneschi; Paola Parronchi; Piero Ruscitti; Maria Cristina Maggio; Ombretta Viapiana; Jurgen Sota; Carla Gaggiano; Roberto Giacomelli; Ludovico Luca Sicignano; Raffaele Manna; Alessandra Renieri; Caterina Lo Rizzo; Bruno Frediani; Donato Rigante; Luca Cantarini
Journal:  Front Med (Lausanne)       Date:  2021-07-08

Review 4.  Biological treatments: new weapons in the management of monogenic autoinflammatory disorders.

Authors:  Antonio Vitale; Donato Rigante; Orso Maria Lucherini; Francesco Caso; Isabella Muscari; Flora Magnotti; Maria Giuseppina Brizi; Susanna Guerrini; Maria Patti; Leonardo Punzi; Mauro Galeazzi; Luca Cantarini
Journal:  Mediators Inflamm       Date:  2013-07-21       Impact factor: 4.711

Review 5.  Update on the management of colchicine resistant Familial Mediterranean Fever (FMF).

Authors:  Georges El Hasbani; Ali Jawad; Imad Uthman
Journal:  Orphanet J Rare Dis       Date:  2019-10-15       Impact factor: 4.123

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.